Sillajen acquirer GFB seeks further partnership opportunity
By | translator Alice Kang
21.06.23 17:35:01
가나다라
0
Focus on ShillaJen’s anticancer virus platform….”Has more potential than other competitors”
"Whether to continue development of Pexa-Vec will be determined after checking future data…such activities will be conducted while establishing a diverse pipeline"
Has deep interest in Korea’s bioindustry…” Will encourage global development based on GFB's extensive BD experience"
"Using ShillaJen’s anticancer virus platform, we can add many new substances to be developed as novel drugs. Korea owns many excellent early-stage novel drug candidates, and we also may additionally introduce promising new substances in Korea."
At the interview with DailyPharm, Ajit Gill, CEO of Greenfire Bio, Ajit Gill expressed his strong will to build additional partnerships with Korean bio-ventures in Korea.
▲CEO Ajit Gill
Greenfire Bio (GFB), a U.S. joint bio-venture firm of M2N that recently acquired Sillajen for 6 billion won, has been established by various industry experts including the company’s CEO Agit Gill who had previously headed Nektar Therapeutics, and CBO Sanjeev Munshi who had serve
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)